Risk of Central Serous Chorioretinopathy in Adults Prescribed Oral Corticosteroids

Tsai, Der‐Chong; Chen, Shih‐Jen; Huang, Chin Chou; Chou, Pesus; Chung, Chia Min; Chan, Wan Leong; Huang, Po Hsun; Lin, Shing Jong; Chen, Jaw Wen; Chen, Tseng Ji; Leu, Hsin Bang

doi:10.1097/iae.0000000000000159

Cited by 57 publications

(60 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tsai et al reported the peak incidence for men was at 35–39 years in a Taiwanese population. They found the highest incidence for women was at 25–29 years and the second higher incidence was at 55–59 years 9. The ethnical variances of the populations may contribute to these discrepancies.…”

Section: Discussionmentioning

confidence: 97%

Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…When considering the route of administration, most series have clearly reported that systemic intake (oral or intravenous) is an independent risk factor for CSCR (Haimovici et al, 2004;Tittl et al, 1999;Tsai et al, 2014;Wakakura et al, 1997). CSCR has also been described after local administration of corticosteroids via the following routes: inhaled and intranasal (Haimovici et al, 1997;Kleinberger et al, 2011), epidural (Iida et al, 2001;Kao, 1998;Pizzimenti and Daniel, 2005), intra-articular (Hurvitz et al, 2009;Kassam et al, 2011;Mondal et al, 2005), topical dermal (Ezra et al, 2011;Fernandez et al, 2004;Karadimas and Bouzas, 2004;Romero et al, 2005) and periocular (Baumal et al, 2004).…”

Section: Corticosteroidsmentioning

confidence: 94%

“…CSCR patients are more likely to have been previously exposed to oral corticosteroid medications, and patients under corticosteroid therapy are at higher risk for developing CSCR (CarvalhoRecchia et al, 2002;Haimovici et al, 2004;Karadimas and Bouzas, 2004;Kitzmann et al, 2008;Tittl et al, 1999;Tsai et al, 2014;Wakakura et al, 1997). When considering the route of administration, most series have clearly reported that systemic intake (oral or intravenous) is an independent risk factor for CSCR (Haimovici et al, 2004;Tittl et al, 1999;Tsai et al, 2014;Wakakura et al, 1997).…”

Section: Corticosteroidsmentioning

confidence: 96%

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Daruich

Matet

Dirani

et al. 2015

Progress in Retinal and Eye Research

818

996

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSCR) is a major cause of vision threat among middle-aged male individuals. Multimodal imaging led to the description of a wide range of CSCR manifestations, and highlighted the contribution of the choroid and pigment epithelium in CSCR pathogenesis. However, the exact molecular mechanisms of CSCR have remained uncertain. The aim of this review is to recapitulate the clinical understanding of CSCR, with an emphasis on the most recent findings on epidemiology, risk factors, clinical and imaging diagnosis, and treatments options. It also gives an overview of the novel mineralocorticoid pathway hypothesis, from animal data to clinical evidences of the biological efficacy of oral mineralocorticoid antagonists in acute and chronic CSCR patients. In rodents, activation of the mineralocorticoid pathway in ocular cells either by intravitreous injection of its specific ligand, aldosterone, or by over-expression of the receptor specifically in the vascular endothelium, induced ocular phenotypes carrying many features of acute CSCR. Molecular mechanisms include expression of the calcium-dependent potassium channel (KCa2.3) in the endothelium of choroidal vessels, inducing subsequent vasodilation. Inappropriate or over-activation of the mineralocorticoid receptor in ocular cells and other tissues (such as brain, vessels) could link CSCR with the known co-morbidities observed in CSCR patients, including hypertension, coronary disease and psychological stress.

show abstract

“…Development of CSCR in cases using systemic steroids usually requires long usage durations and/or high doses of CS [4]. However, a study has reported no relationship between the CS dose and treatment duration and the risk of CSCR development [6]. Koyama et al have reported CS usage durations of 5 days to 23 years in the 17 cases they monitored with CSCR development due to systemic steroid use.…”

Section: Discussionmentioning

confidence: 99%

Central serous chorioretinopathy due to low dose exogenous corticosteroid administered for a bee sting: a complication or coincidence?

Öztürk¹,

Dikçi²,

Demirel³

et al. 2018

Med-Science

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSCR) is a posterior segment disorders characterized by localized and limited serous retinal detachment and/or retinal pigment epithelium detachment. The etiopathogenesis has not been fully elucidated. Local or systemic steroid administration through various routes and endogenous steroid increase are known to cause CSCR. It is believed that steroids cause CSCR development by delaying the healing of retinal pigment epithelium or increase choriocapillaris permeability through various mechanisms. The role of an allergic reaction in CSCR development is controversial. We evaluated a case that developed CSCR following a single intramuscular injection of 8 mg dexamethasone (Dekort, Deva) for a bee sting in this study. The systemic steroid dose used in our case was much lower than other doses reported to cause CSCR in the literature. This suggests that some molecules in the bee venom may have contributed to CSCR development in our case.

show abstract

Risk of Central Serous Chorioretinopathy in Adults Prescribed Oral Corticosteroids

Abstract: Male gender, middle age, and current use of oral corticosteroids were found to be the risk factors for CSCR. However, oral corticosteroids dosage and treatment duration were not associated with the CSCR risk.

Cited by 57 publications

References 24 publications

Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients

Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients

Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis

Central serous chorioretinopathy due to low dose exogenous corticosteroid administered for a bee sting: a complication or coincidence?

Contact Info

Product

Resources

About